LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that C-10068, a novel deuterium-containing sigma-1 agonist, was found to have activity in preclinical models of epilepsy, neuroprotection and neuropathic pain. C-10068 is based on a molecule that was reported to have preclinical anti-convulsant efficacy, but was limited by poor metabolic stability resulting in low oral bioavailability. Applying its DCE Platform™ (deuterated chemical entity platform), Concert improved the compound’s metabolic stability by selective incorporation of deuterium. As a result, in a preclinical model, bioavailability was increased approximately three-fold following oral dosing of C-10068 compared to the non-deuterated molecule. These results were presented by Philip Graham, Ph.D., Vice President, Program Development of Concert Pharmaceuticals, during the Pipeline Day at the Antiepileptic Drug Trials XI Conference in Miami, Florida.
